AstraZeneca Executive Sees Approval Path for Bone-Disease Drug Despite Trial Miss

The head of AstraZeneca’s Alexion rare-disease unit said the company expects its experimental treatment for a rare bone-and-muscle disorder to win regulatory approval, despite missing the main goal of a late-stage clinical trial.